Products
Pomalidomide is commercially available in the form of hard capsules (Imnovid). It has been approved in many countries since 2014. It has been registered in the EU and the United States since 2013.
Structure and properties
Pomalidomide (C13H11N3O4, Mr = 273.2 g/mol) is an amino derivative of thalidomide and a racemate. It is also known as 4-aminothalidomide and exists as a yellow powder that is sparingly soluble in water.
Effects
Pomalidomide (ATC L04AX06) has immunomodulatory, antineoplastic, antiproliferative, and antiangiogenic properties. It inhibits proliferation of hematopoietic tumor cells and induces cell death. At the same time, it also stimulates endogenous antitumor immune responses.
Indications
As a 2nd-line agent in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma.
Dosage
According to the SmPC. Capsules are taken once daily at the same time of day, independent of meals.
Contraindications
- Hypersensitivity
- Pregnancy
- Women capable of childbearing, unless all conditions of the pregnancy prevention program are met.
Full precautions can be found in the drug label.
Interactions
Pomalidomide is a substrate of CYP1A2, CYP3A, and P-glycoprotein.
Adverse effects
The most common potential adverse effects include blood count abnormalities (neutropenia, anemia, thrombocytopenia), fatigue, fever, constipation, and diarrhea. Like thalidomide, pomalidomide also has fertility-disrupting properties.
